On September 2, 2024, Suzhou Chung-Hwa Chemical & Pharmaceutical's parent company, Chung-Hwa Pharmaceutical, which has a 72-year history, was transformed into Chung-Hwa Investment Holdings (3716) and listed, becoming the second pharmaceutical holding company in the Taiwan Stock Exchange. The listed securities of the former China National Chemical Pharmaceutical Co., Ltd. (1701) were delisted and became a wholly-owned subsidiary of Chung-Hwa Holdings.

▲From left to right: Chung-Hwa Pharmaceutical General Manager Wu Zhiyong, Chung-Hwa Silver Hair General Manager Li Zongyong, Chung-Hwa Holdings General Manager and CEO Wang Houkai, Chung-Hwa Yumin General Manager Lin Xuhui. Image source: Internet

The first subsidiary of Chung-Hwa Holdings is Chung-Hwa Pharmaceutical, which focuses on research and development and production. In the future, Chung-Hwa Yumin, which focuses on drug distribution, and Chung-Hwa Silver Hair, which focuses on the elderly field, will be established; related companies and branches include Chung-Hwa Synthesis, Taiwan Rong Development, Chung-Hwa Biomedicine, and Suzhou Chung-Hwa.

The chairman of Chung-Hwa Holdings is Wang Xie Yizhen, and the CEO and general manager is Wang Houkai, the transformation chief of Chung-Hwa Pharmaceuticals. Wang Houkai has extensive experience in foreign investment banks, private equity funds, and industry mergers and acquisitions analysis and execution. He was ordered to return to Taiwan three years ago. He said that the English name of Chung-Hwa Holdings is "CENRA", which is composed of the English word "Center/Central" and the Latin word "Cura". The former means center, and the latter means care, concern and treatment. The Chinese name still continues the "Chung-Hwa" brand that is trusted by customers. At the same time, he also said that the transformation of holdings is the beginning of the group's new milestone. It will promote separate management and integrate resources with the three main axes of "strategic focus", "operation optimization" and "digital leadership" to create a diversified holding platform, and enhance the momentum and efficiency of transformation through the formulation of domestic and foreign industry strategies. He hopes to transform his rich international experience into the group's unique innovative perspective to help the Taiwanese biotechnology and pharmaceutical brand with a history of more than 70 years to shine again.

As a valuable member of Chung-Hwa Investment Holding Co., Ltd., Suzhou Chung-Hwa Chemical & Pharmaceutical has not only inherited its strong resource integration capabilities and global vision, but also achieved remarkable achievements in the field of medicine and health with its own outstanding R&D strength, rigorous production standards and forward-looking market insight. Among them, digestive system drugs: Libofei® Polycarbophil Calcium Tablets, endocrine system drugs: Huayiping® Voglibose Tablets, cardiovascular system drugs: Wenlening® Telmisartan Hydrochlorothiazide Tablets and other systemic drugs have won high recognition from doctors and patients with their significant therapeutic effects.

Facing the future, Suzhou Chung-Hwa Chemical & Pharmaceutical is full of confidence and expectation. It will continue to uphold the corporate spirit of "passion, innovation, care, and health", deepen strategic cooperation with domestic and foreign partners, accelerate the transformation and application of scientific and technological achievements, and promote the high-quality development of the pharmaceutical and health industry. Suzhou Chung-Hwa Chemical & Pharmaceutical firmly believes that through unremitting efforts, it will be able to draw its own glorious chapter in the global pharmaceutical and health landscape and contribute more to the health of mankind!